• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $LQDA

    Liquidia Corporation

    Subscribe to $LQDA
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

    IPO Year: 2018

    Exchange: NASDAQ

    Website: liquidia.com

    Peers

    $UTHR
    $VCYT
    $TVTX

    Recent Analyst Ratings for Liquidia Corporation

    DatePrice TargetRatingAnalyst
    12/20/2024$20.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    8/19/2024Outperform → Strong Buy
    Raymond James
    8/16/2024$27.00Outperform
    Raymond James
    6/25/2024Perform
    Oppenheimer
    1/5/2024$18.00 → $28.00Buy
    Needham
    9/19/2022$3.00Underperform
    Wedbush
    9/1/2022$3.00Neutral → Underperform
    Wedbush
    7/22/2022$15.00Buy
    Ladenburg Thalmann
    5/31/2022$14.00Buy
    BTIG Research
    See more ratings

    Liquidia Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendmentFully enrolled Cohort A of ASCENT study in patients with PH-ILDFurther strengthened financial position via access of up to $100 million from existing financing agreement with HealthCare RoyaltyCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the first quarter ended March 31, 2025. The company will

      5/8/25 6:30:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference

      MORRISVILLE, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced  that the company's Chief Financial Officer and Chief Operating Officer, Michael Kaseta, and Chief Medical Officer, Rajeev Saggar, will provide a business update during a fireside chat at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, beginning at 1:40 p.m. PT / 4:40 p.m. ET in Las Vegas, Nevada. Access to a webcast will be available to investors and other interested parties by accessing Liquidia's website at https://liquidia.com/investors/events-and-pre

      5/6/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

      Court will not hear cross-claim that challenges the PH-ILD indication in the tentatively approved NDA for YUTREPIAFDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 MORRISVILLE, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Judge Kelly of the U.S. District Court for the District of Columbia (District Court) dismissed, without prejudice, the cross-claim filed by United Therapeutics (UTHR) that sought to challenge Liquidia's amendment to its New Drug Application (NDA) for YUTREPIA™ (t

      5/2/25 5:28:34 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

      MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a bioph

      5/1/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

      MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the "Investors" page of Liquidia's website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation will be available on Liquidia's website for at least 30 d

      4/1/25 10:33:25 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

      MORRISVILLE, N.C., April 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the company will provide an overview of the company's business at a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, beginning at 8:45 a.m. ET. Access to a webcast of the presentation will be available on the "Investors" page of Liquidia's website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation will be available on Liquidia's website for at least 30 days following

      4/1/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder

      MORRISVILLE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA confirmed that the resubmission was a complete, Class 1 response to the previous action letter issued on August 16, 2024, which granted tentative approval of YUTREPIA for both PAH and PH-ILD. The F

      3/28/25 9:30:49 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference

      - Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life - Case study highlights the long-term safety and tolerability of LIQ861 (YUTREPIA) in a PAH patient transitioning from parenteral treprostinil in INSPIRE study MORRISVILLE, N.C., March 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the company will present three posters at the American Thoracic Society (ATS) 2025 International Conference, taking p

      3/27/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

      Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil products in clinical studiesStrengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty Partners (HCRx)Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 19, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the full year ended December 31, 2024. The company will also host a webcast at 8:30 a.m. ET on March 19,

      3/19/25 6:30:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million

      MORRISVILLE, N.C., March 18, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that it has entered into a sixth amendment to its agreement with HealthCare Royalty ("HCRx") to provide for up to an additional $100 million of financing in three tranches (the "Sixth Amendment"), subject to certain closing conditions including the funding conditions discussed below. Liquidia intends to use the proceeds to fund ongoing commercial development of YUTREPIA™ (treprostinil) inhalation powder for the potential treatment of pulmonary arterial hypertension (PAH) and pulm

      3/18/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Liquidia Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

      SC 13G/A - Liquidia Corp (0001819576) (Subject)

      11/12/24 5:35:19 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

      SC 13D/A - Liquidia Corp (0001819576) (Subject)

      9/12/24 4:22:57 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

      SC 13D/A - Liquidia Corp (0001819576) (Subject)

      9/4/24 5:51:42 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Liquidia Corporation (Amendment)

      SC 13G/A - Liquidia Corp (0001819576) (Subject)

      2/14/24 4:18:49 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Liquidia Corporation (Amendment)

      SC 13G/A - Liquidia Corp (0001819576) (Subject)

      2/7/24 5:09:04 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Liquidia Corporation

      SC 13G - Liquidia Corp (0001819576) (Subject)

      1/31/24 2:08:28 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Liquidia Corporation

      SC 13G - Liquidia Corp (0001819576) (Subject)

      1/16/24 7:42:57 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Liquidia Corporation (Amendment)

      SC 13D/A - Liquidia Corp (0001819576) (Subject)

      12/14/23 4:40:34 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Liquidia Corporation

      SC 13G - Liquidia Corp (0001819576) (Subject)

      5/5/23 11:52:59 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Liquidia Corporation (Amendment)

      SC 13G/A - Liquidia Corp (0001819576) (Subject)

      2/14/23 4:06:54 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Liquidia Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Liquidia Corporation SEC Filings

    See more
    • Chief Business Officer Adair Jason sold $6,479 worth of shares (455 units at $14.24), decreasing direct ownership by 0.25% to 183,849 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/30/25 4:15:23 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Saggar Rajeev sold $33,492 worth of shares (2,450 units at $13.67), decreasing direct ownership by 0.92% to 263,152 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/23/25 4:15:13 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Schundler Russell sold $80,931 worth of shares (5,964 units at $13.57), decreasing direct ownership by 1% to 570,301 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/16/25 5:06:09 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Jeffs Roger sold $191,744 worth of shares (14,130 units at $13.57), decreasing direct ownership by 1% to 1,006,420 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/16/25 5:05:08 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Moomaw Scott sold $46,219 worth of shares (3,406 units at $13.57), decreasing direct ownership by 2% to 214,744 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/16/25 5:04:17 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and COO Kaseta Michael sold $112,400 worth of shares (8,283 units at $13.57), decreasing direct ownership by 2% to 396,315 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/16/25 5:03:13 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Saggar Rajeev sold $50,399 worth of shares (3,714 units at $13.57), decreasing direct ownership by 1% to 265,602 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/16/25 5:02:40 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Adair Jason converted options into 3,906 shares and sold $25,186 worth of shares (1,856 units at $13.57), increasing direct ownership by 1% to 184,304 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      4/15/25 9:12:44 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Schundler Russell converted options into 2,344 shares and sold $14,368 worth of shares (930 units at $15.45), increasing direct ownership by 0.25% to 576,265 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      3/4/25 4:32:07 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Moomaw Scott converted options into 1,875 shares and sold $9,146 worth of shares (592 units at $15.45), increasing direct ownership by 0.59% to 218,150 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      3/4/25 4:31:35 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Liquidia Corporation

      10-Q - Liquidia Corp (0001819576) (Filer)

      5/8/25 7:00:23 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      5/8/25 6:40:47 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      5/8/25 6:05:36 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      5/5/25 7:00:25 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Liquidia Corporation

      DEFA14A - Liquidia Corp (0001819576) (Filer)

      4/25/25 4:19:23 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Liquidia Corporation

      DEF 14A - Liquidia Corp (0001819576) (Filer)

      4/25/25 4:15:47 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      4/22/25 7:30:31 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Liquidia Corp (0001819576) (Filer)

      3/28/25 4:30:26 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Liquidia Corporation

      EFFECT - Liquidia Corp (0001819576) (Filer)

      3/27/25 12:15:16 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Liquidia Corporation

      S-3 - Liquidia Corp (0001819576) (Filer)

      3/19/25 4:34:02 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Liquidia Corporation FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

      Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

      11/18/21 2:49:33 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Liquidia Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      9/16/24 4:05:20 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      9/4/24 5:51:34 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jeffs Roger bought $1,000,001 worth of shares (139,665 units at $7.16), increasing direct ownership by 28% to 640,805 units (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      12/18/23 5:02:01 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Manning Paul B bought $2,000,003 worth of shares (279,330 units at $7.16) (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      12/18/23 5:00:54 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Caligan Partners Lp bought $7,999,997 worth of shares (1,117,318 units at $7.16) (SEC Form 4)

      4 - Liquidia Corp (0001819576) (Issuer)

      12/14/23 4:42:49 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Liquidia Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wells Fargo initiated coverage on Liquidia Technologies with a new price target

      Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $20.00

      12/20/24 7:42:58 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Liquidia Technologies

      Scotiabank initiated coverage of Liquidia Technologies with a rating of Sector Outperform

      10/16/24 8:39:33 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Technologies upgraded by Raymond James

      Raymond James upgraded Liquidia Technologies from Outperform to Strong Buy

      8/19/24 12:03:58 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James initiated coverage on Liquidia Technologies with a new price target

      Raymond James initiated coverage of Liquidia Technologies with a rating of Outperform and set a new price target of $27.00

      8/16/24 7:36:27 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Liquidia Technologies

      Oppenheimer initiated coverage of Liquidia Technologies with a rating of Perform

      6/25/24 7:57:33 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Liquidia Technologies with a new price target

      Needham reiterated coverage of Liquidia Technologies with a rating of Buy and set a new price target of $28.00 from $18.00 previously

      1/5/24 8:01:13 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush resumed coverage on Liquidia Technologies with a new price target

      Wedbush resumed coverage of Liquidia Technologies with a rating of Underperform and set a new price target of $3.00

      9/19/22 7:46:39 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Technologies downgraded by Wedbush with a new price target

      Wedbush downgraded Liquidia Technologies from Neutral to Underperform and set a new price target of $3.00

      9/1/22 9:06:22 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Liquidia Technologies with a new price target

      Ladenburg Thalmann initiated coverage of Liquidia Technologies with a rating of Buy and set a new price target of $15.00

      7/22/22 7:30:06 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Liquidia Technologies with a new price target

      BTIG Research initiated coverage of Liquidia Technologies with a rating of Buy and set a new price target of $14.00

      5/31/22 7:25:17 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Liquidia Corporation Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

      GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v

      10/2/23 7:00:00 AM ET
      $EBS
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The

      7/21/22 4:30:00 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Appoints Rajeev Saggar, M.D., as Chief Medical Officer

      MORRISVILLE, N.C., June 20, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) ("Liquidia" or the "Company") today announced the appointment of Rajeev Saggar, M.D., to the position of Chief Medical Officer. In this role, Dr. Saggar will oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for Liquidia, assuming responsibilities on July 18, 2022. Roger Jeffs, Chief Executive Officer of Liquidia, said: "We are excited to add a leader of Dr. Saggar's caliber to our team as we prepare for the launch of YUTREPIA™ (treprostinil) inhalation powder upon receipt of final FDA approval. His expertise and credibility in treating patients across a wid

      6/20/22 7:00:11 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation Appoints Michael Kaseta Chief Financial Officer

      RESEARCH TRIANGLE PARK, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta has been appointed Chief Financial Officer (CFO), effective immediately. He succeeds Steve Bariahtaris who has served as Liquidia’s interim CFO since August 2020. Mr. Bariahtaris has agreed to provide assistance to the Company for a short period of time to support a smooth transition. “After an extensive search and thorough review of many outstanding candidates, it is with great pleasure that, today, we welcome Mike Kaseta to the Liquidia team,” said Neal Fowler, Chief Executive Officer at Liquidia. “I am confident that Mike’s financial expertise, business acu

      11/30/20 7:15:00 AM ET
      $SNY
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Liquidia Corporation Financials

    Live finance-specific insights

    See more
    • Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

      MORRISVILLE, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its first quarter 2025 financial results on Thursday, May 8, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a bioph

      5/1/25 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024

      MORRISVILLE, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2024 financial results on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corpora

      11/4/24 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024

      MORRISVILLE, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2024 financial results on August 7, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a bi

      7/31/24 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024

      MORRISVILLE, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its first quarter 2024 financial results on May 14, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location.About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and ot

      5/7/24 8:00:00 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report Third Quarter 2023 Financial Results on November 7, 2023

      MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension

      10/31/23 6:30:15 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report Second Quarter 2023 Financial Results on August 10, 2023

      MORRISVILLE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertensio

      8/3/23 8:17:48 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Corporation to Report First Quarter 2023 Financial Results on May 4, 2023

      MORRISVILLE, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its first quarter 2023 financial results on Thursday, May 4, 2023. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of 30 days at the same location. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and

      4/27/23 6:45:59 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      MORRISVILLE, N.C., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) ("Liquidia" or the "Company") today reported financial results for the third quarter ended September 30, 2022. The Company will host a webcast and conference call at 8:30 a.m. ET to discuss the third quarter 2022 financial results and provide a corporate update. Roger Jeffs, Liquidia's Chief Executive Officer, said: "The third quarter marked a critical juncture in our mission to provide YUTREPIA™ (treprostinil) inhalation powder to patients with PAH and PH-ILD. We have now demonstrated in at least one legal forum that each of the patent claims asserted against us is invalid or not infringed. We will co

      11/8/22 6:30:10 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia to Report Third Quarter 2022 Financial Results on November 8, 2022

      MORRISVILLE, N.C., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The live call may be accessed by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and entering the conference code: 7467713. A webcast of the call will be available and archived for 30 days on Liquidia's website at https://liquidia.com/index.php/investors/events-and-presentations. About Liquidia CorporationLiquidia Corporation is a biopharma

      11/1/22 6:45:16 AM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liquidia Provides Update on Hatch-Waxman Litigation and to Host Call on September 1, 2022, at 8:00am E.T.

      District Court ruling was favorable on ‘066 patent and unfavorable on ‘793 patentAll patent claims asserted have been found to be either invalid or not infringed by District Court or U.S. Patent Trial and Appeal Board (PTAB)PTAB decision to invalidate all claims of ‘793 patent is not affectedAbility to seek final FDA approval of YUTREPIA™ (treprostinil) inhalation powder is contingent on affirmation of the PTAB decision or reversal of District Court decision regarding the ‘793 patent MORRISVILLE, N.C., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that a ruling was issued by Judge Andrews, who is presiding over the litigation filed by United Therapeu

      8/31/22 7:46:18 PM ET
      $LQDA
      Biotechnology: Pharmaceutical Preparations
      Health Care